![]() |
市場調查報告書
商品編碼
2032326
一次性生物反應器市場報告:按產品類型、類別、細胞類型、分子類型、最終用戶和地區分類(2026-2034 年)Single-Use Bioreactors Market Report by Product Type, Type, Cell Type, Molecule Type, End User, and Region 2026-2034 |
||||||
2025年,全球一次性生物反應器市場規模達44億美元。展望未來,IMARC Group預測,到2034年,該市場規模將達到131億美元,2026年至2034年的複合年成長率(CAGR)為12.58%。推動該市場成長的因素包括:生物製藥需求不斷成長、該產品具有成本效益和擴充性、一次性技術的顯著進步、契約製造組織(CMO)的日益普及以及在細胞和基因治療產品生產中應用範圍的擴大。
一次性生物製程技術旨在一次完成生物製藥的過濾、儲存、細胞培養、混合和純化等步驟。該技術經濟高效、省時省力、柔軟性,且易於處置。與傳統生物製程相比,它透過簡化步驟提高了生產效率,並降低了樣品間交叉污染的風險。此外,與鋼製設備相比,它還有助於降低能耗、培養基消耗和碳排放,從而實現永續的生產流程。該技術已被應用於疫苗、植物細胞培養和單株抗體的高效生產。由於減少了人員在設置、驗證和文件記錄方面花費的時間,全球對一次性生物製程技術的需求正在不斷成長。
在全球範圍內,糖尿病、氣喘、關節炎、癌症、高血壓、心臟病、中風和慢性阻塞性肺病(COPD)等慢性疾病的日益普遍是推動市場成長的主要動力。此外,全球範圍內藥物核准和生技藥品數量的不斷成長,帶動了對一次性生物製程的需求,也對市場產生了積極影響。同時,消費者越來越偏好採用高品質聚合物材料和塑膠複合材料製造的產品,因為這些材料能夠實現高強度、一體化的結構,從而為行業投資者創造了極具吸引力的成長機會。此外,一次性生物製程系統帶來的許多優勢,例如降低人事費用、材料和投資成本,也促進了市場成長。此外,人工智慧(AI)、機器學習(ML)和巨量資料解決方案等旨在預測誤差和提高準確性的新技術在一次性生物製程領域的應用,也推動了市場成長。同時,一次性生物製程在培養基製備和生物製藥運輸等領域的廣泛應用,也為市場前景帶來了正面影響。因此,一次性生物製程的應用日益廣泛,因為與傳統生物製程相比,它們能夠減少二氧化碳(CO2)排放,從而推動市場成長。此外,隨著全球醫療設施的發展,一次性生物程序的使用也不斷增加,這也促進了市場成長。
The global single-use bioreactors market size reached USD 4.4 Billion in 2025. Looking forward, IMARC Group expects the market to reach USD 13.1 Billion by 2034, exhibiting a growth rate (CAGR) of 12.58% during 2026-2034. The market is propelled by the increasing demand for biopharmaceuticals, cost-efficiency and scalability offered by the product, significant developments in single-use technology, increasing product adoption in contract manufacturing organizations (CMOs), rising usage in cell and gene therapy production.
Single-use bioprocessing technology is designed for filtration, storage, cell culture, mixing, and purification of biopharmaceutical products for one-time use. It is cost-effective, timesaving, and provides flexibility and hassle-free disposal. It assists in increasing productivity by eliminating complex steps and reduces the risks of cross-contamination among individuals as compared to traditional bioprocessing. Besides this, it is beneficial in reducing energy, media consumption, and carbon footprint and providing a sustainable manufacturing process as compared to steel. It is utilized for the effective production of vaccines, plant cell cultivation, and monoclonal antibodies. As it also reduces the time of staff members for set-up, validation, and documentation, the demand for single-use bioprocessing technology is increasing across the globe.
Presently, the rising prevalence of chronic diseases, such as diabetes, asthma, arthritis, cancer, hypertension, heart attack, stroke, and chronic obstructive pulmonary disease (COPD), among the masses across the globe represents one of the key factors supporting the growth of the market. Apart from this, the growing demand for single-use bioprocessing due to the increasing number of drug approvals and biologics around the world is positively influencing the market. Additionally, rising preferences of products manufactured from high-grade polymer materials and plastic composites, as they offer enhanced integral strength, is offering lucrative growth opportunities to industry investors. Besides this, various benefits offered by single-use bioprocessing systems, such as lower labor, material, and investment costs, are propelling the growth of the market. In addition to this, the emergence of various technological advancements, such as artificial intelligence (AI), machine learning (ML), and big data solutions in single-use bioprocessing for predicting errors and improving accuracy, is bolstering the growth of the market. Moreover, the growing utilization of single-use bioprocessing in media preparation and shipping of biologics while manufacturing pharmaceuticals is offering a favorable market outlook. In line with this, the rising adoption of single-use bioprocessing, as it reduces the amount of carbon dioxide (CO2) compared to traditional bioprocessing, is impelling the growth of the market. Furthermore, the increasing employment of single-use bioprocessing due to the improving healthcare facilities across the globe is contributing to the growth of the market.
The publisher provides an analysis of the key trends in each sub-segment of the global single-use bioprocessing market report, along with forecasts at the global, regional and country levels from 2026-2034. Our report has categorized the market based on product type, application, end-use and, end-user.
The report has also provided a comprehensive analysis of all the major regional markets, which include North America (the United States and Canada); Europe (Germany, France, the United Kingdom, Italy, Spain, Russia, and others); Asia Pacific (China, Japan, India, South Korea, Australia, Indonesia, and others); Latin America (Brazil, Mexico, Argentina, Colombia, Chile, Peru, and others); and the Middle East and Africa (Turkey, Saudi Arabia, Iran, United Arab Emirates, and others). According to the report, North America (the United States and Canada) was the largest market for single-use bioprocessing. Some of the factors driving the North America single-use bioprocessing market included the presence of large-scale manufacturing units, rising geriatric population, increasing healthcare expenditure, etc.
The report has also provided a comprehensive analysis of the competitive landscape in the global single-use bioprocessing market. Competitive analysis such as market structure, market share by key players, player positioning, top winning strategies, competitive dashboard, and company evaluation quadrant has been covered in the report. Also, detailed profiles of all major companies have been provided. Some of the companies covered include Applikon Biotechnology, Boehringer Ingelheim, Cesco Bioengineering Company, Corning Inc., Danaher Corporation, Entegris, Eppendorf AG, Finesse Solutions Inc., GE Healthcare, Infors, Merck Millipore, Rentschler Biotechnologie, Sartorius Stedim Biotech, Thermo Fisher Scientific Inc., 3M Company, etc. Kindly note that this only represents a partial list of companies, and the complete list has been provided in the report.